Dermatology
Long-term Safety and Sustained Control of Atopic Dermatitis in Children Treated with Ruxolitinib Cream: Insights from the Phase 3 TRuE-AD3 Trial
Ruxolitinib cream demonstrates sustained safety and effective disease control over 52 weeks in children aged 2 to 11 years with mild-to-moderate atopic dermatitis, affirming its role as a promising therapeutic option.
